Intellia Therapeutics (NTLA) Equity Average (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Equity Average data on file, last reported at $646.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $646.2 million, down 21.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $646.2 million (down 21.77% YoY), and the FY2025 annual result was $771.7 million, down 19.71% from the prior year.
• Equity Average fell to $646.2 million in Q1 2026 per NTLA's latest filing, from $709.9 million in the prior quarter.
• Over five years, Equity Average peaked at $1.2 billion in Q1 2023 and troughed at $646.2 million in Q1 2026.
• A 5-year average of $933.3 million and a median of $966.8 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 85.84% in 2022, then retreated 25.51% in 2025.
• A 5-year view of Equity Average shows it stood at $1.0 billion in 2022, then increased by 1.31% to $1.0 billion in 2023, then decreased by 12.12% to $917.3 million in 2024, then retreated by 22.61% to $709.9 million in 2025, then decreased by 8.98% to $646.2 million in 2026.
• Business Quant data shows NTLA's Equity Average at $646.2 million in Q1 2026, $709.9 million in Q4 2025, and $731.8 million in Q3 2025.